Associations turn private experiences into public proposals
Cannabis associations influence policy by organizing people, producing proposals and giving evidence to institutions. Two Spanish examples show the process clearly: La Rosa Verda used a citizens’ legislative initiative to bring a club-regulation proposal into Catalonia’s Parliament, while patient advocates appeared in the national Congress’s medical-cannabis hearings in 2022. These are different forms of influence. One sought a framework for consumer associations; the other brought treatment experiences into a medical-policy inquiry.
La Rosa Verda: signatures created a parliamentary route
The Catalan Parliament’s account records 67,500 signatures submitted for the initiative and 54,807 ultimately validated by its control commission. That exceeded the 50,000 needed for parliamentary processing. The resulting law passed in 2017 with broad support on most provisions.
The mechanism is important: signatures did not themselves make club activities lawful. They advanced a defined legislative proposal into debate, where elected representatives could amend and vote on it. An association movement had translated support into an institutional procedure rather than relying only on demonstrations or publicity.
A parliamentary win can still meet a constitutional limit
Law 13/2017 was annulled by Constitutional Court judgment 100/2018. The court found an intrusion into the state’s criminal-law competence. The initiative therefore demonstrates both genuine political influence and the limits of a regional route.
Counting only the vote would miss the legal outcome. Counting only the annulment would miss the movement’s ability to place a detailed proposal before Parliament. Durable reform requires the political coalition and the correct legal competence to align. Public-health arguments may shape a proposal, but they do not transfer national criminal-law powers to a regional legislature.
Patient testimony entered a different debate in 2022
On 9 May 2022, Carola Pérez and Manuel Guzmán appeared before Congress as president and vice-president of the Spanish Observatory of Medicinal Cannabis. The official hearing record placed a patient perspective alongside scientific discussion in the inquiry into medical-cannabis regulation.
This format gives policymakers two kinds of information: how illness and treatment barriers affect everyday life, and what clinical evidence can support a regulated intervention. Personal testimony makes an unmet need visible; it does not by itself establish treatment efficacy. Scientific evidence answers a different question, concerning benefits, harms and the patients to whom findings apply.
Influence is a chain, not ownership of a reform
Royal Decree 903/2025 subsequently established conditions for standardized cannabis preparations used in pharmacy-compounded medicines. The decree is a governmental legal instrument; the existence of earlier advocacy does not prove that any single association caused its provisions.
The documented contribution is more precise. Associations assembled concerns, sustained public discussion and entered formal proceedings. Legislators, the government, courts and medicines authorities retained their distinct powers. This division of roles explains why successful advocacy can change the policy agenda well before it changes the applicable rules—and why medical advocacy and social-club regulation can move at different speeds.
Sources & further reading
General information, not individual legal or medical advice.